CT109-SN-38, a Novel Antibody-drug Conjugate with Dual Specificity for CEACAM5 and 6, Elicits Potent Killing of Pancreatic Cancer Cells.
Arias Cardenas KC, Enos CW, Spear MR, Austin DE, Almofeez R, Kortchak S, Pincus L, Guo HB, Dolezal S, Pierce JM, Furth E, Gineste C, Kwon Y, Gelber C.
Arias Cardenas KC, et al. Among authors: pierce jm.
Curr Cancer Drug Targets. 2024 Jan 4. doi: 10.2174/0115680096260614231115192343. Online ahead of print.
Curr Cancer Drug Targets. 2024.
PMID: 38178674